SCHEMBL3834088

SCHEMBL3834088

CCN(CC)CCCC1(O)CN(C(=O)c2ccc(F)c(F)c2Nc2ccc(I)cc2F)C1

nearest known ligand 0.72

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAP2K1 Q02750 19/20 0.72
MAP2K2 P36507 18/20 0.72
CHRM2 P08172 1/20 0.55
CHRM1 P11229 1/20 0.55
BRAF P15056 1/20 0.55
DRD1 P21728 1/20 0.55
TBXA2R P21731 1/20 0.55
SLC6A2 P23975 1/20 0.55
SLC6A4 P31645 1/20 0.55
ADRA1A P35348 1/20 0.55
OPRM1 P35372 1/20 0.55
DRD3 P35462 1/20 0.55
ACTR3 P61158 1/20 0.55
SLC6A3 Q01959 1/20 0.55
KCNH2 Q12809 1/20 0.55
PIM1 P11309 1/20 0.49
CAMK2B Q13554 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1489064 0.90 MAP2K1 (0.77) MAP2K1MAP2K2CHRM2CHRM1BRAF
SCHEMBL30220888 0.90 MAP2K1 (0.77) MAP2K1MAP2K2CHRM2CHRM1BRAF
SCHEMBL30220858 0.89 MAP2K2 (0.83) MAP2K1MAP2K2CHRM2CHRM1BRAF
SCHEMBL188734 0.89 MAP2K2 (0.83) MAP2K1MAP2K2CHRM2CHRM1BRAF
Acetic Acid SCHEMBL1488777 0.88 MAP2K1 (0.73) MAP2K1MAP2K2CHRM2CHRM1BRAF
Acetic Acid SCHEMBL30221101 0.88 MAP2K1 (0.73) MAP2K1MAP2K2CHRM2CHRM1BRAF
SCHEMBL14300934 0.88 MAP2K2 (0.77) MAP2K1MAP2K2CHRM2CHRM1BRAF
SCHEMBL4577061 0.88 MAP2K1 (0.83) MAP2K1MAP2K2CHRM2CHRM1BRAF
SCHEMBL3833857 0.87 MAP2K1 (0.84) MAP2K1MAP2K2CHRM2CHRM1BRAF
SCHEMBL3832190 0.87 MAP2K1 (0.80) MAP2K1MAP2K2CHRM2CHRM1BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2101759-A1 METHODS OF USING MEK INHIBITORS Exelixis, Inc. (US) 2009-09-23 EP disclosed
WO-2008124085-A2 METHODS OF USING COMBINATIONS OF MEK AND JAK-2 INHIBITORS EXELIXIS, INC. (US) 2008-10-16 WO disclosed
WO-2008076415-A1 METHODS OF USING MEK INHIBITORS EXELIXIS, INC. (US) 2008-06-26 WO disclosed
EP-1934174-A1 AZETIDINES AS MEK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES Exelixis, Inc. (US) 2008-06-25 EP disclosed
WO-2007044515-A1 AZETIDINES AS MEK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES EXELIXIS, INC. (US) 2007-04-19 WO disclosed